Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 6, 1997 - Issue 6
Submit an article Journal homepage
46
Views
11
CrossRef citations to date
0
Altmetric
Meeting Report

American Association for Cancer Research 1997: progress and new hope in the fight against cancer

Francois Lavelle Rhone-Poulenc Rorer SA, Centre de Recherche de Vitry-Alfortville, F94403 Vitry-sur-Seine Cedex, France
Pages 771-775 | Published online: 23 Feb 2005

Bibliography

  • IWATA K, MILLER PE, BARBACCI EG et al: CP358,774: a selective EGFR kinase inhibitor with potent antiprolif-erative activity against 11N5 head and neck tumor cells. Proc. Am. Assoc. Cancer Res. (1997) 38:633. Abstract 4248.
  • POLLACK VA, SAVAGE DM, BAKER DA et al: Therapy of human carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: dynamics of receptor inhibition and anti-tu-mor effects. Proc. Am. Assoc. Cancer Res. (1997) 38:633. Abstract 4249.
  • WOODBURN JR, BARKER AJ, GIBSON KH et al: ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc. Am. Assoc. Can-cer Res (1997) 38:633. Abstract 4251.
  • DIONNE CA, CAMORATTO AM, JANI J eta].: Inhibition of prostate tumor growth by the trk-selective tyrosine kinase inhibitor, CEP-751 (KT-6587). Proc. Am. Assoc. Cancer Res. (1997) 38:634. Abstract 4254.
  • CAMORETTO AM, JANI JP, MURAKATA C, VAUGHT JL, DIONNE CA: CEP-751, a selective trk receptor tyrosine kinase inhibitor, possesses selective anti-tumor action. Proc. Am. Assoc. Cancer Res. (1997) 38:470. Abstract 3147.
  • JANI JP, EMERSON E, CAMORATTO AM et al.: Evaluation of the anti-tumor efficacy of CEP-2563 for the treatment of prostate cancer. Proc. Am. Assoc. Cancer Res. (1997) 38:471. Abstract 3148.
  • DENNY WA, PALMER BD, REWCASTLE GW et al.: Pyrido-D-pyrimidine inhibitors of the tyrosine kinase activity of the EGF receptor: a binding model and structure-ac-tivity relationships for soluble analogues. Proc. Am. Assoc. Cancer Res. (1997) 38:633. Abstract 4250.
  • SUZUKI T, KITANO Y, OHYA J et al.: Novel benzoylacety-lenic compounds: potent and selective EGF receptor tyrosine kinase inhibitors. Proc. Am. Assoc. Cancer Res. (1997) 38:633. Abstract 4252.
  • WOOD J, METT H, STOVER D et al: CGP 41251, an inhibitor of VEGF receptor tyrosine kinases. Proc. Am. Assoc. Cancer Res. (1997) 38:266. Abstract 1787.
  • FONG TAT, MCMAHON G, KIM Yet al.: Small molecule inhibitors of Flk-1 suppress subcutaneous growth of multiple tumor types, inhibit tumor angiogenesis, and provide attenuation of metastasis. Proc. Am. Assoc. Can-cer Res. (1997) 38:266. Abstract 1789.
  • LAVELLE F: American Association for Cancer Research 1996: not a vintage year. Exp. Opin. Invest. Drugs (1996) 5 (6):777–781.
  • NORGAARD P, JOSEPH H, COFFEY RJ et al.: Treatment of mammary gland neoplasia in TGFac transgenic mice with farnesyltransferase inhibitor. Proc. Am. Assoc. Can-cer Res (1997) 38:351. Abstract 2349.
  • LIU M, CHEN P, LEE S et al: SCH 59228, a novel tricyclic inhibitor of farnesyl protein transferase, potently blocks the growth of Ras transformed fibroblasts and human tumor cell lines in nude mice. Proc. Am. Assoc. Cancer Res. (1997) 38:349. Abstract 2341.
  • PRZYBRANOWSKI SA, ELLIOTT WL, LEONARD DM et aL: In vivo evaluation of histidine-(n-benzylglycinad-mides) as inhibitors of ras farnesyltransferase. Proc. Am. Assoc. Cancer Res. (1997) 38:350. Abstract 2344.
  • CIOMEI M, ALBANESE C, PASTORI W etal: Sarcodictyins: a new class of marine derivatives with mode of action similar to Taxol. Proc. Am. Assoc. Cancer Res. (1997) 38:5. Abstract 30.
  • KRUCZYNSKI A, COLPAERT F, TARAYRE JP et al.: In vivoantitumor activity of 12158, a novel fluorinated Vinca alkaloid. Proc. Am. Assoc. Cancer Res. (1997) 38:224. Ab-stract 1511.
  • BARRET JM, KRUCZYNSKI A, ÉTIÉVANT C et al.: Charac-terization o f the in vitroactivity of F 12158, a novel Vinca alkaloid derivative with in vivo antitumor activity. Proc. Am. Assoc. Cancer Res. (1997) 38:226. Abstract 1522.
  • PANDA D, WILLIAMS DC, WAGNER MM et al.: Inhibitionof microtubule polymerisation and dynamics by two novel crytophycins, crytophycins 52 and 55. Proc. Am. Assoc. Cancer Res (1997) 38:225, Abstract 1517.
  • CORBETT T, VALERIOTE F, SIMPSON C et aL: Preclinicalantitumor activity of Cryptophycin-52/55 (C52; C-55) against mouse tumors. Proc. Am. Assoc. Cancer Res. (1997) 38:225. Abstract 1515.
  • WILLIAMS DC, WAGNER MM, LAW KL et al: In vitropharmacology of cryptophycin 52 (LN355703) and cryptophycin 55 (LY355702) in human tumor cell lines. Proc. Am. Assoc. Cancer Res. (1997) 38:226. Abstract 1519.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.